Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation [PDF]
Health Technology Assessment, 2008 Objectives: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with ...
Bayliss, S. +4 more
core +3 more sources
Economic disadvantages of palivizumab [PDF]
Archives of Disease in Childhood, 2000 Editor,—We would fully agree with Dr Sanjeev Deshpande's appraisal of the economic disadvantages of palivizumab ( Arch Dis Child 2000; 82 :88–90) and …
R Boon, R A Smith
openaire +3 more sources
Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants [PDF]
Italian Journal of Pediatrics, 2009 Introduction The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.
Ravasio Roberto +2 more
doaj +2 more sources
PIN23 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE UK [PDF]
, 2005 Lebmeier, M, Nuijten, MJ, Wittenberg, W
core +2 more sources
Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. [PDF]
PLoS ONE, 2017 Monthly injections of palivizumab during the respiratory syncytial virus (RSV) season in at-risk infants reduces RSV-associated hospitalizations. However, the additive effect of naturally acquired immunity remains unclear. The objective of this study was
Jennifer Claydon +9 more
doaj +1 more source
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
Viruses, 2023 (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been ...
Hasindu S. Edirisinghe +10 more
doaj +1 more source
BMC Pediatrics, 2021 Background The prophylactic use of anti-respiratory syncytial virus (RSV) antibody (palivizumab) for severe RSV infection is not approved in Japan in specified groups of infants with neuromuscular diseases or other rare diseases associated with reduced ...
Masaaki Mori +8 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 To date, there is no consensus regarding palivizumab prophylaxis for respiratory syncytial virus infection. The purpose of this study is to assess the effectiveness of palivizumab prophylaxis to prevent respiratory syncytial virus-related infection ...
Natividad Viguria +5 more
doaj +1 more source
Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. [PDF]
PLoS ONE, 2015 To evaluate the safety and tolerability of palivizumab for RSV prophylaxis in high-risk children in everyday practice.High-risk children prophylaxed against RSV infection were recruited into a prospective, observational, Canadian RSV Evaluation Study of ...
Jinghan Jenny Chen +6 more
doaj +1 more source
Foods, 2020 Orally delivered antibodies may be useful for the prevention of enteric pathogen infection, but to be effective they need to survive intact across digestion through the gastrointestinal tract.
Bum Jin Kim +4 more
doaj +1 more source